Gelesis rounds up $3.6M in fresh venture funds

Gelesis, a biotech startup focused on developing new obesity treatments, has raised $3.6 million, reports Globes. The new money brings its total take to date to $20 million. Gelesis was one of FierceBiotech's Fierce 15 in 2010. Story

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.